A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.
Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the
The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug i
Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of
Ampio Pharma's candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review.
A meta-analysis of published studies looking at web-, app- or telehealth-based therapy for osteoarthritis has concluded that they outperform standard approaches to care.